Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why research on hematologic malignancies is ramping up

By Brian Buntz | June 14, 2022

Micrograph of a plasmacytoma.

Micrograph of a plasmacytoma, a hematological malignancy. [Image courtesy of Wikipedia]

Oncology has benefited from a wave of advances in recent decades. From 1991 to 2018, the age-adjusted overall cancer death rate dropped 31%, according to an analysis from American Association for Cancer Research (AACR). That death rate dropped 2.4% between 2017 and 2018, marking the most significant annual reduction.

The reasons for such improvements are multifaceted, including falling smoking rates, improved diagnosis and more effective drugs.

The popularity of immunotherapy has played a vital role in improving treatment outcomes of certain cancers. “It is amazing to think about how much immunotherapy has changed the practice of oncology,” recently wrote Dr. John M. Burke in Targeted Oncology. Burke, a hematologist and medical oncologist at Rocky Mountain Cancer Centers, said data from the past two decades have confirmed the efficacy of monoclonal antibodies, antibody-drug conjugates, checkpoint inhibitors and other therapies.

“We went through a period where immuno-oncology (I-O) had a huge impact on the outcomes on non-small cell lung cancer and melanomas, which used to be almost like a death sentence,” said Jeff Elton, CEO of ConcertAI.

The 5-year relative survival rate for all SEER stages of melanoma skin cancer is 93%, according to the American Cancer Society.

Until recently, treatment of hematological malignancies has lagged relative to solid tumors. However, that is beginning to change. “Now, you’re seeing incredible advances in treating hematological malignancies,” Elton said. “Things like multiple myeloma, follicular lymphoma, whole classes of lymphomas and leukemias are going through a revolution right now in terms of how they’re treated.”

In the past decade, CAR-T cell therapy has emerged as a treatment option for patients with refractory hematologic malignancies.

In the future, treatment of conditions such as multiple myeloma may become so transformative that it is like treating a chronic disease. In the past, the survival rates of such cancers were meager, but “I think you’re already seeing that survival rate and quality of life, extending quite a bit,” Elton said.

Just this month, Janssen announced promising data related to the bispecific antibody teclistamab indicating durable responses in patients with relapsed or refractory multiple myeloma.

Similarly, researchers at Dana-Farber Cancer Institute announced that multiple myeloma patients receiving the combination of Revlimid, bortezomib (Velcade) and dexamethasone improved progression-free survival.

The current 5-year relative survival rate for all SEER-stages of myeloma remains at 56%, according to the American Cancer Society.

For the sake of comparison, the 5-year relative survival rate for multiple myeloma was 3.9 years from 2004 to 2007, according to an analysis in the American Journal of Managed Care.

Elton is optimistic about the rate of improvement. “Now, you’re seeing new approaches that offer tremendous value, sort of like what we saw in solid tumor categories, over the last five to 10 years,” he said. “Some of that’s now coming into the hematological malignancy area, which is very positive and important.”


Filed Under: Oncology
Tagged With: CAR-T, ConcertAI, hematologic malignancies, immunotherapy-oncology, melanoma, oncology
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
AP Biosciences charts course for safer CD137 bispecifics with its T-cube platform
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Why smaller, simpler molecular glues are gaining attention in drug discovery
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE